A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion
- PDF / 7,646,749 Bytes
- 16 Pages / 593.972 x 792 pts Page_size
- 20 Downloads / 229 Views
Annals of Biomedical Engineering (Ó 2020) https://doi.org/10.1007/s10439-020-02590-1
Original Article
A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion ALDO FERRARI,1,3,4 COSTANZA GIAMPIETRO,1,3 BJO¨RN BACHMANN,1 LAURA BERNARDI,4 DEON BEZUIDENHHOUT,5 PAOLO ERMANNI,6 RAOUL HOPF,3,4 SARAH KITZ,9 GERALD KRESS,6 CHRISTIAN LOOSLI,6 VITA MARINA,4 MIRKO MEBOLDT,7 GIOVANNI PELLEGRINI,9 DIMOS POULIKAKOS,1 MATHIAS REBHOLZ,7 MARIANNE SCHMID DANERS ,7 TANJA SCHMIDT,8 CHRISTOPH STARCK,2 GEORGIOS STEFOPOULOS,1 SIMON SU¨NDERMANN,10,2,11 BENTE THAMSEN,7 PETER ZILLA,5 EVGENIJ POTAPOV,2,10,11,12 VOLKMAR FALK,2,10,11,12 and EDOARDO MAZZA3,4 1
Laboratory of Thermodynamics in Emerging Technologies, Department of Mechanical and Process Engineering, ETH Zurich, Sonneggstrasse 3, 8092 Zurich, Switzerland; 2Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany; 3EMPA, Swiss Federal Laboratories for Material Science and Technologies, U¨berlandstrasse 129, 8600 Du¨bendorf, Switzerland; 4Institute for Mechanical Systems, ETH Zurich, 8092 Zurich, Switzerland; 5Christiaan Barnard Division of Cardiothoracic Surgery, University of Cape Town, Cape Town, South Africa; 6Laboratory of Composite Materials and Adaptive Structures, ETH Zurich, 8092 Zurich, Switzerland; 7Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland; 8Julius Wolff Institute and Center for Musculoskeletal Surgery, Charite´ – Universita¨tsmedizin, Berlin, Germany; 9Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland; 10Department of Cardiovascular Surgery, Charite´ Universita¨tsmedizin Berlin, Berlin, Germany; 11Deutsches Zentrum fu¨r Herz-Kreislaufforschung, Standort Berlin, Germany; and 12 Translational Cardiovascular Technologies, Institute of Translational Medicine, Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland (Received 26 February 2020; accepted 11 August 2020) Associate Editor Tingrui Pan oversaw the review of this article.
Abstract—Heart failure is a raising cause of mortality. Heart transplantation and ventricular assist device (VAD) support represent the only available lifelines for end stage disease. In the context of donor organ shortage, the future role of VAD as destination therapy is emerging. Yet, major drawbacks are connected to the long-term implantation of current devices. Poor VAD hemocompatibility exposes the patient to life-
Address correspondence to Aldo Ferrari, Laboratory of Thermodynamics in Emerging Technologies, Department of Mechanical and Process Engineering, ETH Zurich, Sonneggstrasse 3, 8092 Zurich, Switzerland. Electronic mail: aldo.ferrari@empa. chVolkmar Falk, Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany. Electronic mail: [email protected] Mazza, EMPA, Swiss Federal Laboratories for Material Science and Techn
Data Loading...
